Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leonardo Magro

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Blood|September 3, 2017
Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 studyFlorent Malard, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Bone Marrow Transplantation|January 9, 2023
Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)Micha Srour, Tamim Alsuliman, Julien Labreuche, et al.
Bulletin Du Cancer|July 24, 2025
[Management for HSC collected from related donor living in Maghreb for a patient transplanted in a France (SFGM-TC)]Christine Giraud, Virginie Ader, Kahina Amokrane, et al.
Leukemia & Lymphoma|November 1, 2017
Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapyEmmanuelle Le Ray, Lisa Belin, Corine Plancher, et al.
Bone Marrow Transplantation|August 21, 2025
Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesisPaul Chauvet, Cynthia Saade, Julie Demaret, et al.
Bulletin Du Cancer|November 10, 2021
[National patient follow-up care logbook: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Sarah Guenounou, Clotilde Aubrun, Nelly Brancillon, et al.
Blood Advances|October 29, 2021
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experienceAva Diarra, Nicolas Duployez, Elise Fournier, et al.
Bulletin Du Cancer|September 6, 2025
[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)]Tereza Coman, Fabio Andreozzi, Jaques-Olivier Bay, et al.
Bone Marrow Transplantation|May 16, 2019
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndromeThierry Guillaume, Florent Malard, Leonardo Magro, et al.
Bulletin Du Cancer|October 26, 2016
[National patient follow-up care logbook: Guidelines by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Eva de Berranger, Sandie Balcaen, Malika Ainaoui, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Blood|September 3, 2017
Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 studyFlorent Malard, Myriam Labopin, Ibrahim Yakoub-Agha, et al.
Bone Marrow Transplantation|January 9, 2023
Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD): a prospective, multicenter, phase II study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)Micha Srour, Tamim Alsuliman, Julien Labreuche, et al.
Bulletin Du Cancer|July 24, 2025
[Management for HSC collected from related donor living in Maghreb for a patient transplanted in a France (SFGM-TC)]Christine Giraud, Virginie Ader, Kahina Amokrane, et al.
Leukemia & Lymphoma|November 1, 2017
Our experience of solitary plasmacytoma of the bone: improved PFS with a short-course treatment by IMiDs or proteasome inhibitors combined with intensity-modulated radiotherapyEmmanuelle Le Ray, Lisa Belin, Corine Plancher, et al.
Bone Marrow Transplantation|August 21, 2025
Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesisPaul Chauvet, Cynthia Saade, Julie Demaret, et al.
Bulletin Du Cancer|November 10, 2021
[National patient follow-up care logbook: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Sarah Guenounou, Clotilde Aubrun, Nelly Brancillon, et al.
Blood Advances|October 29, 2021
Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experienceAva Diarra, Nicolas Duployez, Elise Fournier, et al.
Bulletin Du Cancer|September 6, 2025
[Acute graft-versus-host disease therapy: Which third line treatment after steroids and ruxolitinib? (SFGM-TC)]Tereza Coman, Fabio Andreozzi, Jaques-Olivier Bay, et al.
Bone Marrow Transplantation|May 16, 2019
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndromeThierry Guillaume, Florent Malard, Leonardo Magro, et al.
Bulletin Du Cancer|October 26, 2016
[National patient follow-up care logbook: Guidelines by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]Eva de Berranger, Sandie Balcaen, Malika Ainaoui, et al.
Pageof 5